Abstract

Liver cancer is in the ten leading cancer types for estimated new cases and deaths in the United States in 2018, and is often detected at late stages when it is rapidly fatal. Of the types of liver cancers in humans, hepatocellular carcinoma (HCC) is the most lethal and prevalent. An important factor in the development of HCC is Farnesoid X Receptor (FXR). FXR acts as master regulator of bile acid homeostasis, and is involved in lipid, cholesterol, and glucose homeostasis. In addition, it plays a protective role against HCC, the precise mechanisms of which has yet to be identified. Ubiquitin Specific Peptidase 2 (USP2) has emerged as a promising area of research for cancer therapy for multiple organ systems. Recent studies have shown USP2 to be involved in a variety of cellular processes ranging from circadian rhythms to tumorigenesis. In particular, USP2 has been studied in lung, bladder, breast, prostate, and ovarian cancer. Additionally, USP2 has 3 distinct isoforms, USP2a, USP2b, and USP2c, all of which have unique functions. In manuscript 1, the purpose of the study was to investigate the isoform specific effects of USP2 in hepatocellular carcinoma (HCC) through the use of healthy human liver samples compared to tumor samples, paired human liver tumor and surrounding samples, paired mouse liver tumor and surrounding samples, and the immortalized liver cancer cell line HepG2. Of the three USP2 isoforms, USP2a and USP2b are the most abundant in human and murine liver. Both USP2a and USP2b levels are significantly lower in HCC compared to healthy liver samples. In paired tumor and surrounding liver samples from mice and human, USP2b is consistently decreased within the tumor compared to the surrounding tissue. USP2b was decreased in tumors in all human samples and decreased in over 80% of murine samples. This suggests as the state of the liver worsens in HCC pathology, USP2b will also decrease. In HepG2 cells, both USP2a and USP2b isoforms led to increased proliferation, colony formation, and wound healing. Additionally, USP2b and USP2c lead to increased migration, wound healing, and apoptosis. Previous studies have only recognized USP2b as a circadian gene, making this the first study to report involvement of USP2b in cellular processes beyond its circadian characteristics. Overall, USP2a and USP2b have opposing roles in HCC development, with USP2a displaying a tumor-promotion role and USP2b displaying a tumor-protective role. In manuscript 2, we present a novel potential mechanism

Highlights

  • IntroductionOf importance in maintenance of proper protein levels is rate of synthesis and rate of degradation

  • The purpose of this study was to investigate the isoform specific effects of Ubiquitin Specific Peptidase 2 (USP2) in hepatocellular carcinoma (HCC) through the use of healthy human liver samples compared to tumor samples, paired human liver tumor and surrounding samples, paired mouse liver tumor and surrounding samples, and the immortalized liver cancer cell line HepG2

  • The results demonstrated that hepatic USP2a expression was significantly deceased in HCC subjects when compared to normal subjects

Read more

Summary

Introduction

Of importance in maintenance of proper protein levels is rate of synthesis and rate of degradation. It is important to note that USP2 has multiple isoforms due to alternative splicing of 5’ exons [3], all of which have different actions and expression levels within cells. USP2a (NM_004205), known as variant 1 or USP2-69, encodes the longest isoform with 619 amino acids. USP2b (NM_171997), known as variant 2 or USP2-45, is a shorter isoform comprised of 396 amino acids and a different N-terminus. FXR has a variety of important functions in the liver in both metabolic and non-metabolic processes. It is the master regulator of bile acid homeostasis, and plays a critical role in lipid, cholesterol, and glucose homeostasis [9–15]. The mechanism by which FXR signaling protects against HCC development is still unclear

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call